These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

58 related articles for article (PubMed ID: 19570506)

  • 1. TEL me all.
    Sloma I; Eaves CJ
    Cell Stem Cell; 2009 Jul; 5(1):5-6. PubMed ID: 19570506
    [TBL] [Abstract][Full Text] [Related]  

  • 2. TEL-AML1 corrupts hematopoietic stem cells to persist in the bone marrow and initiate leukemia.
    Schindler JW; Van Buren D; Foudi A; Krejci O; Qin J; Orkin SH; Hock H
    Cell Stem Cell; 2009 Jul; 5(1):43-53. PubMed ID: 19570513
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A previously unidentified alternatively spliced isoform of t(8;21) transcript promotes leukemogenesis.
    Yan M; Kanbe E; Peterson LF; Boyapati A; Miao Y; Wang Y; Chen IM; Chen Z; Rowley JD; Willman CL; Zhang DE
    Nat Med; 2006 Aug; 12(8):945-9. PubMed ID: 16892037
    [TBL] [Abstract][Full Text] [Related]  

  • 4. AML1-ETO targets and suppresses cathepsin G, a serine protease, which is able to degrade AML1-ETO in t(8;21) acute myeloid leukemia.
    Jin W; Wu K; Li YZ; Yang WT; Zou B; Zhang F; Zhang J; Wang KK
    Oncogene; 2013 Apr; 32(15):1978-87. PubMed ID: 22641217
    [TBL] [Abstract][Full Text] [Related]  

  • 5. AML1-ETO triggers epigenetic activation of early growth response gene l, inducing apoptosis in t(8;21) acute myeloid leukemia.
    Fu L; Huang W; Jing Y; Jiang M; Zhao Y; Shi J; Huang S; Xue X; Zhang Q; Tang J; Dou L; Wang L; Nervi C; Li Y; Yu L
    FEBS J; 2014 Feb; 281(4):1123-31. PubMed ID: 24314118
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression differences in TEL-AML1 fusion gene in leukemia glucocorticoid-sensitive and -resistant cell lines.
    Wang XW; Xu YH
    Genet Mol Res; 2015 Jul; 14(3):7883-93. PubMed ID: 26214469
    [TBL] [Abstract][Full Text] [Related]  

  • 7. LPXN, a member of the paxillin superfamily, is fused to RUNX1 in an acute myeloid leukemia patient with a t(11;21)(q12;q22) translocation.
    Dai HP; Xue YQ; Zhou JW; Li AP; Wu YF; Pan JL; Wang Y; Zhang J
    Genes Chromosomes Cancer; 2009 Dec; 48(12):1027-36. PubMed ID: 19760607
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Modeling first-hit functions of the t(12;21) TEL-AML1 translocation in mice.
    Tsuzuki S; Seto M; Greaves M; Enver T
    Proc Natl Acad Sci U S A; 2004 Jun; 101(22):8443-8. PubMed ID: 15155899
    [TBL] [Abstract][Full Text] [Related]  

  • 9. AML1 and the AML1-ETO fusion protein in the pathogenesis of t(8;21) AML.
    Licht JD
    Oncogene; 2001 Sep; 20(40):5660-79. PubMed ID: 11607817
    [No Abstract]   [Full Text] [Related]  

  • 10. Multi-sites cleavage of leukemogenic AML1-ETO fusion protein by caspase-3 and its contribution to increased apoptotic sensitivity.
    Lu Y; Peng ZG; Yuan TT; Yin QQ; Xia L; Chen GQ
    Leukemia; 2008 Feb; 22(2):378-86. PubMed ID: 17989718
    [TBL] [Abstract][Full Text] [Related]  

  • 11. TEL (ETV6)-AML1 (RUNX1) initiates self-renewing fetal pro-B cells in association with a transcriptional program shared with embryonic stem cells in mice.
    Tsuzuki S; Seto M
    Stem Cells; 2013 Feb; 31(2):236-47. PubMed ID: 23135987
    [TBL] [Abstract][Full Text] [Related]  

  • 12. AML1/ETO and POU4F1 synergy drives B-lymphoid gene expression typical of t(8;21) acute myeloid leukemia.
    Dunne J; Mannari D; Farzaneh T; Gessner A; van Delft FW; Heidenreich O; Young BD; Gascoyne DM
    Leukemia; 2012 May; 26(5):1131-5. PubMed ID: 22064348
    [No Abstract]   [Full Text] [Related]  

  • 13. The AML1 gene: a transcription factor involved in the pathogenesis of myeloid and lymphoid leukemias.
    Lo Coco F; Pisegna S; Diverio D
    Haematologica; 1997; 82(3):364-70. PubMed ID: 9234595
    [TBL] [Abstract][Full Text] [Related]  

  • 14. RNA interference and deep sequencing as tools for identifying new genes involved in leukemogenesis.
    Lebedev TD; Spirin PV; Orlova NN; Kudryavtseva AV; Melnikova NV; Speranskaya AS; Prasolov VS
    Dokl Biochem Biophys; 2013; 448():49-51. PubMed ID: 23478988
    [No Abstract]   [Full Text] [Related]  

  • 15. Childhood leukemia genetic bottleneck phenomenon related to TEL-AML1: the postulation by a mathematical model.
    Ivanovski P; Ivanovski I; Nikolić D; Jovanović I
    Chin Med J (Engl); 2012 Mar; 125(6):1182-5. PubMed ID: 22613552
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clonotypic analysis of acute lymphoblastic leukemia with a double TEL-AML1 fusion at onset and relapse.
    Inukai T; Yokota S; Okamoto T; Nemoto A; Akahane K; Takahashi K; Sato H; Goi K; Nakazawa S; Sugita K
    Leukemia; 2006 Feb; 20(2):363-5. PubMed ID: 16357830
    [No Abstract]   [Full Text] [Related]  

  • 17. Transcription of the AML1/ETO chimera is guided by the P2 promoter of the AML1 gene in the Kasumi-1 cell line.
    Markova EN; Kantidze OL; Razin SV
    Gene; 2012 Dec; 510(2):142-6. PubMed ID: 22995345
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pediatric acute lymphoblastic leukemia: there is no TEL-ing what wonders lie ahead.
    Sandoval C
    Leuk Res; 2010 Apr; 34(4):418-9. PubMed ID: 19892401
    [No Abstract]   [Full Text] [Related]  

  • 19. JAK2 seems to be a typical cooperating mutation in therapy-related t(8;21)/ AML1-ETO-positive AML.
    Schnittger S; Bacher U; Kern W; Haferlach C; Haferlach T
    Leukemia; 2007 Jan; 21(1):183-4. PubMed ID: 17096014
    [No Abstract]   [Full Text] [Related]  

  • 20. TEL/AML1-positive patients lacking TEL exon 5 resemble canonical TEL/AML1 cases.
    Zaliova M; Meyer C; Cario G; Vaskova M; Marschalek R; Stary J; Zuna J; Trka J
    Pediatr Blood Cancer; 2011 Feb; 56(2):217-25. PubMed ID: 21157892
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.